Point-of-Care Glucose Testing Size Analysis and Top Companies
The global point-of-care glucose testing market size is expected to reach around USD 5.28 billion by 2033 from USD 3.50 billion in 2023, expanding at a CAGR of 4.2% from 2024 to 2034. The top compnaies operating in the point-of-care glucose testing market are Abbott, Dexcom, Roche, Ascensia Diabetes Care, LifeScan, Medtronic, Ypsomed, Animas, Insulet, Bayer, Nipro, Terumo, Arkray, Acon Laboratories, Freestyle, One Touch, Accu-Chek, Dario, iHealth, FreeStyle Libre, and Others.
Market Report Coverage
| Report Coverage |
Details |
| Growth Rate from 2024 to 2033 |
CAGR of 4.2% |
| Global Market Size in 2023 |
USD 3.50 Billion |
| Global Market Size in 2024 |
USD 3.65 Billion |
| Global Market Size by 2033 |
USD 5.28 Billion |
| Largest Market |
North America |
| Base Year |
2023 |
| Forecast Period |
2024 to 2033 |
| Segments Covered |
By Product, By Application, and By End User |
| Regions Covered |
North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Point-of-Care Glucose Testing Key Players
- Abbott (U.S.)
- Dexcom (U.S.)
- Roche (Switzerland)
- Ascensia Diabetes Care (Switzerland)
- LifeScan (U.S.)
- Medtronic (U.S.)
- Ypsomed (Switzerland)
- Animas (U.S.)
- Insulet (U.S.)
- Bayer (Germany)
- Nipro (Japan)
- Terumo (Japan)
- Arkray (Japan)
- Acon Laboratories (U.S.)
- Freestyle (U.S.)
- One Touch (U.S.)
- Accu-Chek (Germany)
- Dario (U.S.)
- iHealth (China)
- FreeStyle Libre (UK)
Recent Developments
- In February 2024, Trinity Biotech (TRIB) finalized a conclusive agreement to purchase the biosensor and Continuous Glucose Monitoring (CGM) assets from Waveform Technologies. This strategic acquisition, valued at $12.5 million in cash and 9 million American Depositary Shares (ADSs) of the company, alongside additional considerations, positions Trinity Biotech to innovate diabetes care and upgrade its presence in the biosensor market.
- In July 2023, Avricore Health and Ascensia Diabetes Care revealed a partnership to incorporate blood glucose monitoring into point-of-care testing. The collaboration seeks to integrate the Contour Next-Gen and Contour Next One BGM systems into Avricore’s HealthTab PCOT platform.
- In June 2023, the initial locally produced continuous glucose monitoring device was approved by the South Korean Ministry of Food and Drug Safety. I-SENS, the manufacturer of blood glucose devices, introduced CareSens Air, which claimed to be the most compact and lightweight CGM device accessible in South Korea. It can be utilized continuously for 15 days and incorporates a calibration mechanism to enhance the accuracy of readings.
- In January 2022, Roche introduced the Cobas Pulse, a point-of-care blood glucose monitor meant for hospital personnel, along with a companion gadget structured like a touchscreen smartphone that will run its apps. The Cobas pulse will begin shipping to certain European countries with a CE mark.
We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344
